Undisclosed antiretroviral drug use in a multinational clinical trial (HIV prevention trials network 052)

Jessica M. Fogel, Lei Wang, Teresa L. Parsons, San San Ou, Estelle Piwowar-Manning, Ying Chen, Victor O. Mudhune, Mina C. Hosseinipour, Johnstone Kumwenda, James G. Hakim, Suwat Chariyalertsak, Ravindre Panchia, Ian Sanne, Nagalingeswaran Kumarasamy, Beatriz Grinsztejn, Joseph Makhema, Jose Pilotto, Breno R. Santos, Kenneth H. Mayer, Marybeth McCauleyTheresa Gamble, Namandjé N. Bumpus, Craig W. Hendrix, Myron S. Cohen, Susan H. Eshleman

Research output: Contribution to journalArticlepeer-review

Abstract

The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to selfreport of ARV drug use in some clinical trial settings.

Original languageEnglish (US)
Pages (from-to)1624-1628
Number of pages5
JournalJournal of Infectious Diseases
Volume208
Issue number10
DOIs
StatePublished - Nov 15 2013

Keywords

  • Africa
  • Antiretroviral drug
  • Clinical trial
  • HIV
  • HPTN 052
  • Self-report

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Undisclosed antiretroviral drug use in a multinational clinical trial (HIV prevention trials network 052)'. Together they form a unique fingerprint.

Cite this